ArticleCancers2022
Quantifying Tumor Heterogeneity via MRI Habitats to Characterize Microenvironmental Alterations in HER2+ Breast Cancer.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- A Machine Learning Model Based on Unsupervised Clustering Multihabitat to Predict the Pathological Grading of Meningiomas.BioMed research international · 2022Trial
- Utilization of MRI-based radiomics nomogram for predicting HER2-zero, -low, and -overexpression breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The value of non-enhanced magnetic resonance imaging based on T2-weighted imaging and apparent diffusion coefficient in the study of three-tiered HER2 status in patients with breast cancer.Quantitative imaging in medicine and surgery · 2026Article
- MRI-based habitat and peritumoral radiomics for predicting HER2 status in breast cancer: a multicenter study.Scientific reports · 2026Article
- Predicting head and neck cancer response to radiotherapy using mathematical modeling of MRI-based habitats.NPJ precision oncology · 2026Article
- A multicenter study on preoperative WHO/ISUP grading of clear cell renal cell carcinoma using triphasic contrast-enhanced CT-based habitat imaging.BMC medical imaging · 2026Article
- Multicenter study provides radiomic and biological insights into neoadjuvant chemotherapy response and prognosis in luminal breast cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- A SHAP-interpretable XGBoost model: MRI-based intratumoral perfusion heterogeneity predicts HER2-zero, -low, and -positive ternary expression status in breast cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Cellularity habitat-based MRI radiomics for non-invasive grading and IDH mutation prediction in adult-type diffuse glioma.BMC medical imaging · 2026Article
- Dual deep learning approach for non-invasive renal tumour subtyping with VERDICT-MRI.Npj imaging · 2026Article
- Fractal analysis of tumor subregions differentiates benign from malignant breast lesions.Polish journal of radiology · 2026Article
- A study on the prognostic assessment of triple-negative breast cancer using habitat analysis of preoperative DCE-MRI subtraction maps.Frontiers in oncology · 2026Article
- The role of magnetic resonance imaging (MRI) in breast cancer molecular subtypes.Polish journal of radiology · 2026Review
- Application of multimodal fusion technology in early recurrence prediction and pathological analysis of hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- Predicting the response of triple negative breast cancer to neoadjuvant systemic therapy via biology-based modeling and habitat analysis.Scientific reports · 2025Article
- MRI-based Habitat Imaging for Noninvasive Prediction of High-Grade Prostate Cancer.Radiology. Imaging cancer · 2025Article
- A narrative review of imaging intratumor heterogeneity in non-small cell lung cancer: current advances.Translational lung cancer research · 2025Review
- Development and application of a novel tumor habitat analysis technique based on dynamical modeling.Medical physics · 2025Article
- Multiparametric MRI-Based Intratumoral and Peritumoral Radiomics for Distinguishing Solitary Intrahepatic Mass-Forming Cholangiocarcinoma From Colorectal Liver Metastases.Cancer medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study identifies physiological habitats using quantitative magnetic resonance imaging (MRI) to elucidate intertumoral differences and characterize microenvironmental response to targeted and cytotoxic therapy. BT-474 human epidermal growth factor receptor 2 (HER2+) breast tumors were imaged before and during treatment (trastuzumab, paclitaxel) with diffusion-weighted MRI and dynamic contrast-enhanced MRI to measure tumor cellularity and vascularity, respectively. Tumors were stained for anti-CD31, anti-ɑSMA, anti-CD45, anti-F4/80, anti-pimonidazole, and H&E. MRI data was clustered to identify and label each habitat in terms of vascularity and cellularity. Pre-treatment habitat composition was used stratify tumors into two "tumor imaging phenotypes" (Type 1, Type 2). Type 1 tumors showed significantly higher percent tumor volume of the high-vascularity high-cellularity (HV-HC) habitat compared to Type 2 tumors, and significantly lower volume of low-vascularity high-cellularity (LV-HC) and low-vascularity low-cellularity (LV-LC) habitats. Tumor phenotypes showed significant differences in treatment response, in both changes in tumor volume and physiological composition. Significant positive correlations were found between histological stains and tumor habitats. These findings suggest that the differential baseline imaging phenotypes can predict response to therapy. Specifically, the Type 1 phenotype indicates increased sensitivity to targeted or cytotoxic therapy compared to Type 2 tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.